Drug Trial News

RSS

Global study confirms pantoprazole's role in reducing upper GI bleeding in the ICU

A widely available drug helps prevent upper gastrointestinal bleeding in critically ill adults on a breathing machine, according to the results of a global study and meta-analysis led by researchers at McMaster University.

14 Jun 2024

MEK inhibitor trametinib shows potential in pediatric JMML treatment

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years.

13 Jun 2024

First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer can be treated safely with the cellular immunotherapy with promising therapeutic activity, according to the phase 1 trial study published today in Nature Medicine.

12 Jun 2024

Crinecerfont: A promising compound for reducing corticosteroid dependence in CAH patients

People born with the common form of congenital adrenal hyperplasia lack an enzyme in the adrenal glands needed to make the hormones cortisol and aldorsterone, which are involved in the body's response to stress and blood pressure regulation.

10 Jun 2024

Clinical trial demonstrates efficacy of two-drug therapy for methamphetamine addiction

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests.

10 Jun 2024

Stanford study finds 15-day paxlovid treatment safe but ineffective for long COVID

In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid -; an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19 -; proved safe as an extended-duration treatment but didn't lessen select symptoms of the syndrome known as long COVID: the persistence, or reappearance, of COVID-related symptoms three months or more after an initial COVID-19 infection.

7 Jun 2024

New hope for BCG-unresponsive bladder cancer patients with innovative combination therapy

In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.

6 Jun 2024

Phase III trial highlights benefits of intensity modulated proton therapy for oropharyngeal cancer

According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of chemoradiation treatment for patients with oropharyngeal (head and neck) cancer.

6 Jun 2024

New bilateral gene therapy shows promising results in treating genetic hearing loss

A novel gene therapy designed to target a form of inherited deafness restored hearing function in five children who were treated in both ears.

5 Jun 2024

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.

4 Jun 2024

SU2C-SARC032 trial: Immunotherapy reduces relapse risk in soft tissue sarcoma by 43%

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues.

4 Jun 2024

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

Clinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).

3 Jun 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

SELECT trial shows semaglutide reduces kidney decline in obese patients

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.

25 May 2024

Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

24 May 2024

Phase 1 trial for EBC-129 progresses into dose expansion

The Experimental Drug Development Centre (EDDC), Singapore's national platform for drug discovery and development, is pleased to announce that the Phase 1 trial for EBC-129 has progressed into dose expansion.

24 May 2024

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.

20 May 2024

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug -; dupilumab -; that showed rapid and sustained improvements in patients in a pivotal Phase 3 clinical trial, researchers report in the New England Journal of Medicine.

20 May 2024

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models.

20 May 2024

1
2
3
4
...
1136
Next

Drug Trial News

Global study confirms pantoprazole's role in reducing upper GI bleeding in the ICU

MEK inhibitor trametinib shows potential in pediatric JMML treatment

First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Crinecerfont: A promising compound for reducing corticosteroid dependence in CAH patients

Clinical trial demonstrates efficacy of two-drug therapy for methamphetamine addiction

Stanford study finds 15-day paxlovid treatment safe but ineffective for long COVID

New hope for BCG-unresponsive bladder cancer patients with innovative combination therapy

Phase III trial highlights benefits of intensity modulated proton therapy for oropharyngeal cancer

New bilateral gene therapy shows promising results in treating genetic hearing loss

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

SU2C-SARC032 trial: Immunotherapy reduces relapse risk in soft tissue sarcoma by 43%

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

RNA-based therapy shows promise in reducing cholesterol and triglycerides

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

SELECT trial shows semaglutide reduces kidney decline in obese patients

Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

Phase 1 trial for EBC-129 progresses into dose expansion

Donepezil fails to enhance cognitive abilities in breast cancer survivors: Phase III trial results

Dupilumab shows promising results in Phase 3 trial for COPD with type 2 inflammation

Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News